摘要
目的分析坦索罗辛联合艾司西酞普兰治疗慢性骨盆疼痛综合征的临床疗效、症状改善和炎症水平的影响。方法选取2022年1月至2023年1月收治的慢性骨盆疼痛患者120例作为研究对象(参考Kendall样本量估计方法,样本量:观察变量的10~20倍,预计估算量:60~120个),随机数表法分为对照组和观察组,每组60例。对照组给予坦索罗辛治疗,观察组给予坦索罗辛联合艾司西酞普兰治疗,疗程均为2个月。比较2组患者治疗前、后的排尿症状、炎性因子水平、临床指标和症状积分变化情况,对比2组患者的不良反应发生情况。结果观察组患者的尿频尿急、尿后滴沥、排尿疼痛评分和总积分均低于对照组(P<0.05);观察组治愈率显著高于对照组(P<0.05);观察组白细胞计数(WBC)、白介素-1β(IL-1β)、干扰素-α(INF-α)均低于对照组,平均尿流率(AFR)、白细胞介素-2(IL-2)均高于对照组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论坦索罗辛联合艾司西酞普兰治疗慢性骨盆疼痛综合征有助于改善临床症状和临床指标、抑制炎性反应,临床疗效较好。
Objective To comprehensively analyze the clinical efficacy,symptom improvement and inflammation level of tamsulosin combined with escitalopram in the treatment of chronic pelvic pain syndrome(CPPS).Methods A total of 120 patients with CPPS admitted to our hospital from January 2022 to January 2023 were enrolled and divided into control group(n=60)and observation group(n=60)by a random number table.All patients were treated with tamsulosin,those in the observation group were additionally treated with escitalopram.A 2-months of treatment was performed,aiming to compare urination symptoms,inflammatory factor levels,clinical indicators,symptom scores,and incidence of adverse reactions between groups before and after treatment.Results After treatment,the dimension scores and total scores of urinary frequency,urgency,dripping or a stream of urine,urination-induced pain score of the observation group were significantly lower than those of the control group(P<0.05).The cure rate of the observation group was significantly higher than that of the control group(P<0.05).The levels of white blood cell count(WBC),interleukin-1 beta(IL-1beta),interferon(INF)-alpha of the observation group were significantly lower than the control group,while the average urinary flow rate(AFR)and interleukin-2(IL-2)were significantly higher(P<0.05).The incidence of adverse reactions in the observation group was comparable to the control group(P>0.05).Conclusion Tamsulosin combined with escitalopram in the treatment of chronic pelvic pain syndrome is helpful to improve clinical symptoms and clinical indicators,inhibit inflammatory reaction,and has a good clinical efficacy.
作者
孙景存
陈维
王江静
张洪亮
SUN Jingcun;CHEN Wei;WANG Jiangjing(Department of Western Medicine,Cangzhou Hospital of Integrated TCM-WMHebei,Hebei,Cangzhou 061001,China)
出处
《河北医药》
CAS
2024年第16期2462-2465,共4页
Hebei Medical Journal
基金
河北省卫生健康委员会科学研究课题(编号:20190967)。
